Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP615751.RAlgZNaB84EDnMBKHOCeQ-qESLLvLkXfRiAHrQg7fROWM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP615751.RAlgZNaB84EDnMBKHOCeQ-qESLLvLkXfRiAHrQg7fROWM130_assertion type Assertion NP615751.RAlgZNaB84EDnMBKHOCeQ-qESLLvLkXfRiAHrQg7fROWM130_head.
- NP615751.RAlgZNaB84EDnMBKHOCeQ-qESLLvLkXfRiAHrQg7fROWM130_assertion description "[In this article we describe the variants in genes that influence either the efficacy or toxicity of common drugs used in the treatment of inflammatory bowel diseases (IBD), ulcerative colitis (UC), and Crohn's disease (CD) including sulfasalazine and mesalazine, azathioprine (AZA) and 6-mercaptopurine (6-MP), methotrexate (MTX), glucocorticosteroids (CSs) and infliximab.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP615751.RAlgZNaB84EDnMBKHOCeQ-qESLLvLkXfRiAHrQg7fROWM130_provenance.
- NP615751.RAlgZNaB84EDnMBKHOCeQ-qESLLvLkXfRiAHrQg7fROWM130_assertion evidence source_evidence_literature NP615751.RAlgZNaB84EDnMBKHOCeQ-qESLLvLkXfRiAHrQg7fROWM130_provenance.
- NP615751.RAlgZNaB84EDnMBKHOCeQ-qESLLvLkXfRiAHrQg7fROWM130_assertion SIO_000772 16773681 NP615751.RAlgZNaB84EDnMBKHOCeQ-qESLLvLkXfRiAHrQg7fROWM130_provenance.
- NP615751.RAlgZNaB84EDnMBKHOCeQ-qESLLvLkXfRiAHrQg7fROWM130_assertion wasDerivedFrom befree-20140225 NP615751.RAlgZNaB84EDnMBKHOCeQ-qESLLvLkXfRiAHrQg7fROWM130_provenance.
- NP615751.RAlgZNaB84EDnMBKHOCeQ-qESLLvLkXfRiAHrQg7fROWM130_assertion wasGeneratedBy ECO_0000203 NP615751.RAlgZNaB84EDnMBKHOCeQ-qESLLvLkXfRiAHrQg7fROWM130_provenance.